SCHEMBL5875758

SCHEMBL5875758

CCC(NC(=O)Cc1cc(F)cc(F)c1)C(=O)Nc1nc2ccc(OC)cc2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.64
RAB9A P51151 5/20 0.64
CSNK1D P48730 9/20 0.62
ATAD2 Q6PL18 1/20 0.60
SMN1; SMN2 Q16637 3/20 0.58
TSHR P16473 1/20 0.58
CASP2 P42575 1/20 0.56
MEN1 O00255 1/20 0.56
SCD O00767 1/20 0.56
KMT2A Q03164 1/20 0.56
ALDH1A1 P00352 1/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 2/20 0.55
WNT3A P56704 2/20 0.55
CYP1A2 P05177 1/20 0.54
CYP2C19 P33261 1/20 0.54
HTT P42858 1/20 0.54
DYRK1A Q13627 1/20 0.54
PSEN1 P49768 2/20 0.54
PSEN2 P49810 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16992953 1.00 NPC1 (0.64) NPC1RAB9ACSNK1DATAD2SMN1; SMN2
SCHEMBL5875681 0.89 PSEN1 (0.58) NPC1RAB9ACSNK1DSMN1; SMN2MEN1
SCHEMBL5875689 0.88 PSEN1 (0.55) CSNK1DDYRK1APSEN1PSEN2APH1B
SCHEMBL8260317 0.80 KMT2A (0.63) NPC1RAB9ASMN1; SMN2TSHRMEN1
SCHEMBL5875524 0.80 KMT2A (0.63) NPC1RAB9ASMN1; SMN2TSHRMEN1
SCHEMBL5875506 0.79 PSEN1 (0.69) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5875772 0.77 PSEN1 (0.54) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL17287785 0.77 CSNK1D (1.00) NPC1RAB9ACSNK1DSMN1; SMN2TSHR
SCHEMBL5875822 0.77 PSEN1 (0.56) MEN1KMT2AALDH1A1PSEN1PSEN2
SCHEMBL3099320 0.76 PSEN1 (0.58) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006504796-A 2006-02-09 JP claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP claimed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US claimed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO claimed
EP-1551815-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2005-07-13 EP disclosed
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders PFIZER INC 2004-08-05 US disclosed
WO-2004033439-A1 THIAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152747-A1 Thiazole compounds for treatment of neurodegenerative disorders APP, PARK7, IAPP NPC1 83/4885RAB9A 1184/4885CSNK1D 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.